Kara L Calkins1, Thomas Havranek2,3, Lorraine I Kelley-Quon4, Laura Cerny2, Martiniano Flores5, Tristan Grogan6, Stephen B Shew7. 1. 1 David Geffen School of Medicine, University of California, Los Angeles, and Mattel Children's Hospital at UCLA, Department of Pediatrics, Division of Neonatology and Developmental Biology, Neonatal Research Center of the UCLA Children's Discovery and Innovation Institute, Los Angeles, California, USA. 2. 2 Department of Pediatrics, Division of Neonatology, St Louis University School of Medicine, Cardinal Glennon Children's Hospital, St Louis, Missouri, USA. 3. 3 Department of Pediatrics, Division of Neonatology, Albert Einstein College of Medicine, Bronx, New York, USA. 4. 4 Department of Surgery, Division of General Surgery, David Geffen School of Medicine, University of California, Los Angeles, California, USA. 5. 5 Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, California, USA. 6. 6 Department of Medicine, Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, California, USA. 7. 7 Department of Surgery, Division of Pediatric Surgery, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Abstract
BACKGROUND:Neonates with gastrointestinal disorders (GDs) are at high risk for parenteral nutrition-associated liver disease (PNALD). Soybean-based intravenous lipid emulsions (S-ILE) have been associated with PNALD. This study's objective was to determine if a lower dose compared with a higher dose of S-ILE prevents cholestasis without compromising growth. MATERIALS AND METHODS: This multicenter randomized controlled pilot study enrolled patients with GDs who were ≤5 days of age to a low dose (~1 g/kg/d) (LOW) or control dose of S-ILE (~3 g/kg/d) (CON). The primary outcome was cholestasis (direct bilirubin [DB] >2 mg/dL) after the first 7 days of age. Secondary outcomes included growth, PN duration, and late-onset sepsis. RESULTS: Baseline characteristics were similar between the LOW (n = 20) and CON groups (n = 16). When the LOW group was compared with the CON group, there was no difference in cholestasis (30% vs 38%, P = .7) or secondary outcomes. However, mean ± SE DB rate of change over the first 8 weeks (0.07 ± 0.04 vs 0.3 ± 0.09 mg/dL/wk, P = .01) and entire study (0.008 ± 0.03 vs 0.2 ± 0.07 mg/dL/wk, P = .02) was lower in the LOW group compared with the CON group. CONCLUSION: In neonates with GDs who received a lower dose of S-ILE, DB increased at a slower rate in comparison to neonates who received a higher dose of S-ILE. Growth was comparable between the groups. This study demonstrates a need for a larger, randomized controlled trial comparing 2 different S-ILE doses for cholestasis prevention in neonates at risk for PNALD.
RCT Entities:
BACKGROUND: Neonates with gastrointestinal disorders (GDs) are at high risk for parenteral nutrition-associated liver disease (PNALD). Soybean-based intravenous lipid emulsions (S-ILE) have been associated with PNALD. This study's objective was to determine if a lower dose compared with a higher dose of S-ILE prevents cholestasis without compromising growth. MATERIALS AND METHODS: This multicenter randomized controlled pilot study enrolled patients with GDs who were ≤5 days of age to a low dose (~1 g/kg/d) (LOW) or control dose of S-ILE (~3 g/kg/d) (CON). The primary outcome was cholestasis (direct bilirubin [DB] >2 mg/dL) after the first 7 days of age. Secondary outcomes included growth, PN duration, and late-onset sepsis. RESULTS: Baseline characteristics were similar between the LOW (n = 20) and CON groups (n = 16). When the LOW group was compared with the CON group, there was no difference in cholestasis (30% vs 38%, P = .7) or secondary outcomes. However, mean ± SE DB rate of change over the first 8 weeks (0.07 ± 0.04 vs 0.3 ± 0.09 mg/dL/wk, P = .01) and entire study (0.008 ± 0.03 vs 0.2 ± 0.07 mg/dL/wk, P = .02) was lower in the LOW group compared with the CON group. CONCLUSION: In neonates with GDs who received a lower dose of S-ILE, DB increased at a slower rate in comparison to neonates who received a higher dose of S-ILE. Growth was comparable between the groups. This study demonstrates a need for a larger, randomized controlled trial comparing 2 different S-ILE doses for cholestasis prevention in neonates at risk for PNALD.
Authors: Erika Tomsits; Margit Pataki; Andrea Tölgyesi; György Fekete; Katalin Rischak; Lajos Szollár Journal: J Pediatr Gastroenterol Nutr Date: 2010-10 Impact factor: 2.839
Authors: Rafeeq Muhammed; Ronald Bremner; Sue Protheroe; Tracey Johnson; Chris Holden; M Stephen Murphy Journal: J Pediatr Gastroenterol Nutr Date: 2012-06 Impact factor: 2.839
Authors: Brian T Kalish; Hau D Le; Jonathan M Fitzgerald; Samantha Wang; Kyle Seamon; Kathleen M Gura; Karsten Gronert; Mark Puder Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-10-03 Impact factor: 4.052
Authors: Annika Mutanen; Markku J Nissinen; Jouko Lohi; Päivi Heikkilä; Helena Gylling; Mikko P Pakarinen Journal: Am J Clin Nutr Date: 2014-08-06 Impact factor: 7.045
Authors: Orly L Levit; Kara L Calkins; L Caroline Gibson; Lorraine Kelley-Quon; Daniel T Robinson; David A Elashoff; Tristan R Grogan; Ning Li; Matthew J Bizzarro; Richard A Ehrenkranz Journal: JPEN J Parenter Enteral Nutr Date: 2014-06-24 Impact factor: 4.016
Authors: Kara L Calkins; James C Y Dunn; Stephen B Shew; Laurie Reyen; Douglas G Farmer; Sherin U Devaskar; Robert S Venick Journal: JPEN J Parenter Enteral Nutr Date: 2013-07-26 Impact factor: 4.016
Authors: Karim C El Kasmi; Aimee L Anderson; Michael W Devereaux; Padade M Vue; Wujuan Zhang; Kenneth D R Setchell; Saul J Karpen; Ronald J Sokol Journal: Sci Transl Med Date: 2013-10-09 Impact factor: 17.956
Authors: Meredith A Baker; Paul D Mitchell; Alison A O'Loughlin; Alexis K Potemkin; Lorenzo Anez-Bustillos; Duy T Dao; Gillian L Fell; Kathleen M Gura; Mark Puder Journal: JPEN J Parenter Enteral Nutr Date: 2017-12-06 Impact factor: 4.016
Authors: Kara L Calkins; Andrea DeBarber; Robert D Steiner; Martiniano J Flores; Tristan R Grogan; Susanne M Henning; Laurie Reyen; Robert S Venick Journal: JPEN J Parenter Enteral Nutr Date: 2017-12-18 Impact factor: 3.896